Measurement of levels of infliximab and anti-infliximab antibodies in rheumatic patients

Status

Not yet recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2013-004969-14-FI

Enrollment

150

Registered

2014-01-15

Start date

2014-01-28

Completion date

Unknown

Last updated

2014-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rheumatic diseases MedDRA version: 16.1 Level: PT Classification code 10072736 Term: Rheumatic disorder System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders

Interventions

Trade Name: Remicade Pharmaceutical Form: Infusion INN or Proposed INN: INFLIXIMAB CAS Number: 170277-31-3

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with infliximab therapy Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 150 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 50

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Main Objective: study the levels of infliximab and anti-infliximab antibodies in rheumatic patients;Secondary Objective: not applicable;Primary end point(s):	—

Countries

Finland

Contacts

Public ContactTampere University Hospital

Heidi Mäkinen

heidi.m.makinen@pshp.fi

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026